56982-15-1

Basic information

• Product Name: 2-methyl-3-(3-carboxyphenyl)-quinazolin-4(3H)-one
• Synonyms: 2-methyl-3-(3-carboxyphenyl)-quinazolin-4(3H)-one
• CAS NO: 56982-15-1
• Molecular Weight: 280.283
• Mol File: 56982-15-1.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 2-methyl-3-(3-carboxyphenyl)-quinazolin-4(3H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-methyl-3-(3-carboxyphenyl)-quinazolin-4(3H)-one(56982-15-1)
• EPA Substance Registry System: 2-methyl-3-(3-carboxyphenyl)-quinazolin-4(3H)-one(56982-15-1)

Safety Data

• Hazardous Substances Data: 56982-15-1(Hazardous Substances Data)

Upstream product

• 525-76-8 2-methyl-4-oxo-3,1-benzoxazine 
• 118-92-3 anthranilic acid 
• 89-52-1 o-acetylamino-benzoic acid 
• 56982-16-2 3-(2-methyl-4-oxo-4H-quinazolin-3-yl)-benzoic acid methyl ester 
• 4518-10-9 Methyl 3-aminobenzoate 

Relevant articles and documents

Reaction of Solid Acetylanthranil with Methanol Vapor: High Specificity and Enhanced Reactivity

-

Structure-Activity Relationship for the 4(3H)-Quinazolinone Antibacterials

We recently reported on the discovery of a novel antibacterial (2) with a 4(3H)-quinazolinone core. This discovery was made by in silico screening of 1.2 million compounds for binding to a penicillin-binding protein and the subsequent demonstration of antibacterial activity against Staphylococcus aureus. The first structure-activity relationship for this antibacterial scaffold is explored in this report with evaluation of 77 variants of the structural class. Eleven promising compounds were further evaluated for in vitro toxicity, pharmacokinetics, and efficacy in a mouse peritonitis model of infection, which led to the discovery of compound 27. This new quinazolinone has potent activity against methicillin-resistant (MRSA) strains, low clearance, oral bioavailability and shows efficacy in a mouse neutropenic thigh infection model.

QUINAZOLINONE ANTIBIOTICS

A new class of antibiotics effective against methicillin-resistant Staphylococcusaureus (MRSA) is disclosed. Compounds of this class can impair cell-wall biosynthesis by binding to both the allosteric and the catalytic domains of penicillin-binding protein (PBP) 2a. This class of antibiotics holds promise in reversing obsolescence of staphylococcal PBPs as important targets for antibiotics. Embodiments of the invention thus provide novel antibacterial compounds that target penicillin-binding proteins and/or other important cellular targets. Methods for inhibiting the growth and/or replication of bacteria using the compounds described herein are also provided. Various embodiments exhibit activity against gram positive bacteria, including drug-resistant strains of Staphylococcus aureus.